HRH4
Histamine H4 receptor
As of the edition of 20 October 2026, HRH4 (histamine H4 receptor, UniProt Q9H3N8) has 4 drugs tested at it and 6 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9H3N8
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 15
- Disease areas
- Immune system; Skin and connective tissue; Bones, joints and muscles; Inherited and neonatal; Lungs and airways; Blood and lymph; Cancer; Ear, nose and throat
- Registered trials of its drugs
- 17
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 3 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Toreforant | Went quiet | Phase 2 | none listed |
| Adriforant | Stopped | Phase 2 | none listed |
| SENS-111 | Went quiet | Phase 2 | none listed |
| UR-63325 | Went quiet | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Novartis | Route A |
| Sensorion | Route A |
| Johnson & Johnson | Route A |
The other 3 companies at HRH4
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at HRH4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.